Three Decades of Amyloid Beta Synthesis: Challenges and Advances

Johanes K Kasim; Iman Kavianinia; Paul W R Harris; Margaret A Brimble

doi:10.3389/fchem.2019.00472

Three Decades of Amyloid Beta Synthesis: Challenges and Advances

Front Chem. 2019 Jul 2:7:472. doi: 10.3389/fchem.2019.00472. eCollection 2019.

Authors

Johanes K Kasim¹, Iman Kavianinia^{1

2

3}, Paul W R Harris^{1

2

3}, Margaret A Brimble^{1

2

3}

Affiliations

¹ School of Biological Sciences, The University of Auckland, Auckland, New Zealand.
² Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.
³ School of Chemical Sciences, The University of Auckland, Auckland, New Zealand.

Abstract

Aggregation of the pathological amyloid beta (Aβ) isoform Aβ_1-42 into senile plaques is a neuropathological hallmark of Alzheimer's disease (AD). The biochemical significance of this phenomenon therefore necessitates the need for ready access to Aβ_1-42 for research purposes. Chemical synthesis of the peptide, however, is technically difficult to perform given its propensity to aggregate both on resin during solid phase peptide synthesis and in solution during characterization. This review presents a chronological summary of key publications in the field of Aβ_1-42 synthesis, dating back from its maiden synthesis by Burdick et al. Challenges associated with the preparation of Aβ_1-42 were identified, and the solutions designed over the course of time critically discussed herein. Ultimately, the intention of this review is to provide readers with an insight into the progress that has been made in the last three decades, and how this has advanced broader research in AD.

Keywords: Alzheimer's disease; amyloid beta; dementia; difficult peptide sequences; neurodegenerative disorders; peptide chemistry; solid phase peptide synthesis.

Publication types

Review